alexa Long Term Protease Inhibitor Monotherapy in a Two-Tiered HIV-1 Levels Design | OMICS International
ISSN 2155-6113
Journal of AIDS & Clinical Research

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Long Term Protease Inhibitor Monotherapy in a Two-Tiered HIV-1 Levels Design

Ernest ND1* and Michael C1,2

1Research Service and Development, VA Medical Center, Irving Avenue Syracuse, NY, USA

2Department of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA

*Corresponding Author:
Ernest ND
Research Service and Development (151)
VA Medical Center, 800 Irving Avenue Syracuse
NY 13210d, USA
Tel: 315 425- 4865
E-mail: [email protected]

Received date September 12, 2016; Accepted date September 24, 2016; Published date September 30, 2016

Citation: Ernest ND, Michael C (2016) Long Term Protease Inhibitor Monotherapy in a Two-Tiered HIV-1 Levels Design. J AIDS Clin Res 7: 619. doi:10.4172/2155-6113.1000619

Copyright: © 2016 Ernest ND, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Visit for more related articles at Journal of AIDS & Clinical Research

Abstract

Treatment of choice in ART therapy for HIV-1 viremia remains an issue as all treatments interrupt HIV repopulation albeit at different reproductive points. The issue was addressed by grouping patients into two-tiered HIV level design of High >50,000 and Low <50,000 plasma cps/ml. The High group with 3 patients had combined class ART using NRTI plus NNRTI or PI regimens until viremia was reduced to <75 cps/ml and then PI alone. The Low group with 11 patients had PIMT regimen. CD4 T cell levels were monitored throughout. ART efficacy was assessed as total number of months of controlled (<75 cps/ml) viral infection level vs. number of months of uncontrolled levels of (>75 cps/ml). In that adherence/non-adherence to regimen is a confound, it was also assessed by rate of suppression: HIVj-HIVk/ HVj-HVn. In the High group, one patient attained long term controlled HIV viremia over 56 months vs. 3 months of uncontrolled viremia while the other two patients (21 vs. 25; 9 vs. 11) did not. Corresponding values in Group 2 ranged from 6 months to 139 months vs. <5 months A t-test for correlated means (with control for duration differences) showed significant difference: t=4.10, α=<0.01, df=10. Suppression rates, both within and across groups, were from: 0.99-1.0 of cps/ml. Accordingly, PI monotherapy can maintain long term viremia suppression for viral levels of <50,000 cps/ml and ART is operative within an inferred functionally closed boundary system as no host characterization including CD4 T cell level affected ART outcome.

Keywords

HIV-1; PIMT; Pharmacotherapeutic; Efficacy; ART; Interaction; Efficacy

Introduction

The goal of antiretroviral therapy (ART) is long term suppression of HIV in plasma. Current standard recommended therapeutic options include use of protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) combined with two nucleoside reverse transcriptase inhibitors (NRTI) for high viral loads (>75,000 cps/ml) as well as for long term maintenance at <40 cps/ml [1]. Using protease inhibitors in combination with NNRTI can be problematic due to potential development of drug resistance and consequent loss of treatment options [1-4]. Recent licensure of many alternative drugs targeting protease and reverse transcriptase as well as newer class inhibitors such as INSTI (integrase inhibitors) and CCR5 (co-receptor blocker) provide effective counters to resistance as well as to other untoward side effects.

The need for life long therapy for HIV infection includes the potential risk of drug toxicities, drug interactions and high maintenance costs particularly in developed countries around the globe. Several randomized clinical trials examined the efficacy of PIMT (protease inhibitor monotherapy [4-9]. Reviews of the literature, however, show lack of agreement on PIMT efficacy [10-14]. Following an earlier study Paton [15] examined this issue with a TR (truly random) non-inferiority study comparing standard combined class inhibitor regimens vs. single class protease inhibitor regimens for long term maintenance of suppression at <50 cps/ml. The results confirmed both the expectation of PIMT efficacy for long term suppression and that of showing non-inferiority of PIMT on rebound frequency, loss of treatment option, as well as drug intolerance and toxic effects in comparison with combined class therapy. Altogether, the results of at least these two studies suggest that PI monotherapy might be the way forward for maintaining sustained HIV-1 suppression [16,17].

The present two-tiered retrospective study was designed to assess the efficacy of combined class ART using NRTI plus NNRTI or PI regimens followed by PI regimen to attain and maintain suppression (<75 cps/ml) for starting viral loads of >50,000 cps/ml in one group; and, in a second group, by using PI regimens for starting viral loads of <50,000 cps/ml. The specific issue addressed was whether <50,000 cps/ ml viral load levels could be suppressed and sustained by PI regimen on a long term basis. Simply put, is <50,000 cps/ml the new threshold at which PI regimens alone could both attain and sustain long term suppression of HIV viral load?

Materials and Methods

Patients

Fourteen patients comprised the present retrospective study. Upon inspection of patient records, no host characterization variables were observed to contribute to ART efficacy; i.e., age, comorbidity and other state of health monitors. This outcome, therefore, did not provide a rational basis for a need to randomize patients into assigned groups. Patient assignment was based on initial pretreatment HIV plasma viral load levels (cps/ml). Accordingly, two treatment groups were formed from the HIV outpatient population in the VA Medical Center at Syracuse, NY: Group I, high >50,000 cps/ml; and, Group II, low <50,000 cps/ml of plasma HIV.

ART regimens

Combined class treatment regimen was used for patients with high HIV viral load levels starting at >50,000 cps/ml plasma RNA HIV viral loads until viremia was suppressed to >75 cps/ml. It was then followed by PIMT for maintenance of the suppressed viremia. For patients in the Low group (<50,000 cps/ml), PIMT was used throughout except when resistance would occur and then the treatment was switched to another PI drug; or, if PI options were lost altogether, to a combined multiclass regimen.

In the Low Group, of the 11 patients one had a 3NRTI regimen; and, one other patient had a 2NRTI/1NNRTI combination treatment prior to initiation of the PI regimen. Patient appointments (observation intervals) were within a range of one to six months; and, rarely, only one week apart. HIV viral loads were monitored throughout to chart viremia suppression as well as co-morbidities such as: hepatitis C, cancer, renal failure requiring dialysis and others.

Treatment efficacy assessments

The number of months of controlled viremia (<75 cps/ml) vs. number of months of uncontrolled viremia (>75 cps/ml) was one measure of efficacy. However, given the inherent confound of adherence/non-adherence in this measure, a second direct measure was used, not found in the extant literature. This was the rate measure of suppression expressed as a mathematical ratio of differences. When applied to HIV-1 viremia, it would take the form: HIVj-HIVk/HIVj- HIVn where the two numerator values of HIVj and HIVk represent plasma viral load levels (cps/ml) at first and second observations; whereas, the denominator value of HIVj-HIVn represents the total unsuppressed viral load (cps/ml). That is, treatment effect in the formula above shows partial/over total possible reduction of cps/ml at any period of the regimen.

Resistance mutations and CD4 T cell levels

Resistance mutations were documented as they occurred. Patients showing resistance were switched to an alternative drug from the same class. When there were no options left, the switch was to a combined multiclass 2NRTI/1NNRTI regimen. CD4 T cell levels were monitored throughout; but, as CD4 T cell count levels appeared to be unrelated to treatment efficacy, they were monitored only intermittently in the last two years.

Results

Group I high HIV viral level >50,000 cps/ml

Table 1 shows patient ID, age, co-morbidity and other patient characteristics for Group I, including treatment and outcome as well as current health status of the patient. Observation intervals were from 1 to 4 months As can be seen from Table 1, when PI therapy was started, following the initial multiclass combined treatment, the controlled levels of HIV (<75 cps/ml) were sustained over a long duration: 53 months vs. 3 months for patient 1; but, not for patients 2 and 3. The corresponding results were: 21 vs. 25 and 9 vs. 11 months, respectively. Patient 2 was poorly adherent; and, not surprisingly, developed resistance. He was off therapy for 2 years; but, was suppressed on the subsequent PI regimen for almost 4 years at which point he required more intensive treatment regimen. Patient 3 developed resistance to atazanavir and was then treated with rilpivirine, tenofovir and emtricitabine.

Suppression rate, the second measure calculated as a ratio of differences, indicated high efficacy; i.e., rates of suppression ranged from 0.99-1.00 of the available cps/ml without variation, either within or across patients. These results showing high ART efficacy with both measures were immediate and there was no evidence of change; nor, of progressive additive ART effects over time.

Group II low HIV viral level <50,000 cps/ml

Table 2 shows patient information, treatment and treatment outcome results for Group 2. As can be seen from Table 2, all patients attained long term controlled HIV load levels of <75 cps/ml over the course of treatment vs. <5 months of uncontrolled levels except for one patient who did respond to ART and did show periods of suppression; but who, nonetheless, did not attain long term sustained suppression with either ATZ/r (atazanavir/ritonavir), DAR/r (darunavir/ritonavir); nor, with the earlier LOP/r (lopanavir/ritonavir) regimen. However, the patient did claim adherence throughout. A test for drug resistance mutations was negative; but, the test was performed early in the course of treatment. In spite of failure to achieve sustained viral suppression, he was asymptomatic regarding his HIV infection for 6 years with a viral loads usually below 500 cps/ml and a stable >200 CD4 T cell count; altogether a stable, sustainable and tolerable outcome. A t-test for correlated means of controlled and uncontrolled number of months (following transformation into unit normal scores to control for treatment duration differences) indicated a statistically significant effect of PIMT regimen in controlling HIV-1 levels at <75 cps/ml: t=4.10, α=<0.01, df=10.

Patient Age Co-morbidity Prior Regimen Current Regimen Highest VL copies/ml before PIMT Duration on PIMT regimen Current VL Current CD4 Outcome and Present Status
1 77 Hep C- Cancer EMT/TEN
ATZ/r
ATZ/r 177,800 56 M
Controlled
53
Uncontrolled
3
<1 331 (29) Well suppressed on prior regimen EMT/TEN.
Discontinued due to elevated creatinine
2 64 Hep C+ STA+LAM +ABC TIP/r
RAL
TEN
56,209 46 M
Controlled
21
Uncontrolled
25
46 393 (26) Poorly adherent patient. Previously on 3 NRTI’s. He developed resistance to NRTI’s and then stopped therapy for 2 years. After, he remained suppressed on LOP/r for almost 4 years; then showed poor control of viral load and was switched to DAR/r without improvement. Viral load suppressed on present regimen for several years
3 57 Hep C- LOP/r RIL
EMT
TEN
53100 20 M
Controlled
9
Uncontrolled
11
277 439 (20) Well suppressed before changing the regimen. Intermittently suppressed while on PIMT; however, he developed resistance to ATZ.
Since starting rilpivirine/EMT/TEN, he has been suppressed for 30 months

Table 1: Antiretroviral efficacy of protease inhibitor monotherapy (PIMT) for patients with high initial viral load >50000 cps/ml.

Patient Age Co-morbidity Prior Regimen Current Regimen Highest VL copies/ml before PIMT Duration on PIMT regimen Current VL Current CD4 Outcome and Present Status
1 62 Hep C+ STA+TEN+LAM ATZ/r 43100 142 M
Controlled
139
Uncontrolled
3
<1 386 (14) Started to simplify therapy
Well suppressed
2 44 Hep C- ZDV
+LAM +TEN
ATZ/r 14951 72 M
Controlled
71
Uncontrolled
1
<1 225 (37) Well suppressed
3 56 Hep C- Naive ATZ/r 17970 18 M
Controlled
18
Uncontrolled
0
<40 1167 (30) Doing well on PIMT regimen
4 60 Hep C+
Prostate
cancer
Naive ATZ/r 10905 79 M
Controlled
7 9 Uncontrolled
0
91 303 (16) Doing well on PIMT regimen
5 64 Hep C+ Naive LOP/r   42700 34 M
Controlled
31
Uncontrolled
3
<75 358 (32) Achieved suppression while on chronic dialysis. Dead due to cardiac failure
6 53 Hep C- Naive DAR/r 26800 74 M
Controlled
4
Uncontrolled
70
84 540 (25) Chronic dialysis; patient started on LOP/r. Switched to ATZ/r then DAR/r due to failure to achieve viral suppression
7 62 Hep C- Naive DAR/r 23777 78 M
Controlled
74
Uncontrolled
4
<1 443 (19) Achieved suppression with DAR/r
8 43 Hep C- Naive ATZ/r 48756 16 M
Controlled
16
Uncontrolled
0
43 689 (44) Suppressed on ATZ/r
9 53 Hep C- ZDV
LAM
ABC
ATZ/r 28944 58 M
Controlled
58
Uncontrolled
0
<1 516 (50) Suppressed on ATZ/r
10 65 Hep C-
Anal
cancer
diabetes
Naive ATZ/r 17500 30 M
Controlled
25
Uncontrolled
5
<1 780 (27) Initially non-adherent; however, when he became adherent, ATZ/r suppressed his viral load
11 60 Hep C-
diabetes
Naive ATZ/r 17970 9 M
Controlled
6
Uncontrolled
3
<40 1167 (30) Suppressed on ATZ/r

Table 2: Antiretroviral efficacy of protease inhibitor monotherapy (PIMT) for patients with low initial viral load <50000cps/ml.

Rate of viral load suppression was also assessed with the standard rate formula described above. As in Group I, the values for the first and second assessment again showed a high rate of suppression ranging from 0.99-1.00 of the available cps/ml, except for the one patient who did not achieve sustained suppression; but who, nonetheless, showed rate scores of 0.98, 0.98 and 1.00. Observation intervals ranged from 1-5 months although one patient had not been seen over a period of 6 months with no impact on rate scores.

The high ART efficacy rate observed in Group II is consistent with the results for Group I that had the combined multiclass treatment regimens of NRTI, NNRTI and PIMT. Accordingly, this observed convergence in outcome in spite of treatment differences, leaves the question of choice of combined vs. single class regimens on factors other than treatment efficacy; both were equally effective. Moreover, the ART effects were immediate, not additive, and sample size did not matter as illustrated by the sample size differences between Group I and Group II with no differential impact on the treatment efficacy. This last observation has some relevance and significance.

CD4 t assessment and ART efficacy

CD4 t levels were without impact and showed no consistent pattern in relation to ART efficacy over the longitudinal treatment time line. A correlational analysis in relation to reduction of HIV viral load was not carried out in view of the fact that CD4 t was monitored only intermittently in the last 2 years

Discussion

The results, overall, of the fourteen patients, with one exception, suggest that the two-tiered treatment strategy of categorizing patients into high (>50,000 cps/ml) and low HIV (<50,000 cps/ml) viral load levels was sustained. The question whether <50,000 cps/ml is susceptible to PIMT and thus becoming the new upper threshold for PIMT was also answered by positive result outcomes. Drug resistance was detected in two instances of the first group (<50,000 cps/ml); and, this is consistent with earlier expectations [18].

In conclusion, PIMT should be considered as a potential option for maintaining suppressed HIV viral load levels even for thresholds as high as <50,000 cps/ml) once suppression is achieved by combined multiclass regimen. In instances of patients of low initial viremia levels, PIMT might be an effective choice to attain and sustain suppressed viremia starting at threshold levels as high as <50,000 in place of the current standard <50 cps/ml [14,15].

The significance of the CD4 T cell count, which varied among patients, is that this is the only functional point of contact of host to HIV virus. It was, however without impact on treatment outcome what this last observation suggests is that patient variability in age and other state of health monitors play no role in the HIV viral load level × ART efficacy interaction; thus, eliminating the need for randomization of patient assignment into treatment groups. Instead, the significance of the CD4 T observed lack of effect on treatment outcome lies in the parametric limitations it places on the interpretation of the treatment x HIV interaction outcome.

Regarding the issue of choice of drug regimen, the observed results allow no precise rational basis for choice as shown by the high and equal ART efficacy rate (0.9-1.0 kill rate of cps/ml) for both combined class as well as PI monotherapy within and across patients; thus, factors other than efficacy would determine choice (economic cost, adherence, tolerance, toxicity, and other side effects).

The present results can be conceptualized as falling into a framework model consisting of two domains (or systems). The first domain is the interactive plasma HIV viral load × ART that is operative within a functionally closed boundary system [19] in which no exteroceptive environmental or interoceptive host patient characterizations such as age, co-morbidities, Hepatitis C, cancer, renal deficits, etc. impact upon the HIV load level × ART interaction efficacy. This is indirectly supported by the observation of high ART efficacy in the two outcome measures regardless of combined or single class therapy regimens. The second domain is the integrated HIV genome into the memory CD4 T cells Here, ART is ineffective as the HIV virus in the memory CD4 T cells is stable and remains in a non-replicative state [20-22].

Certain expectations follow from the above conceptualization of the present findings: (1) random assignment in research studies of patients to ART treatment is not necessary; (2) ART efficacy rate constant within and across groups (k=0.99-1.0) suggests a marker for objective determination of adherence/non-adherence in patients and as an independent check on patient self-reports. (3) If ART treatment is effective in one patient, it will be effective in other patients, save for drug resistant HIV mutation and/or non-adherence. (4) Cohort size in ART efficacy studies is irrelevant except for long term observation of resistance, side effects and/or non-adherence (5). Patient differences in response to drug regimens are largely due to side effects and/or differences in drug absorption. (6) Considerable economy in lifetime treatment costs in the developed world is likely were conclusion (4) sustained by further studies.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

  • Global experts meet on STD - AIDS and Infectious Diseases
    May 30-31, 2018 Auckland, New Zealand
  • 6th World Congress on Control and Prevention of HIV/AIDS , STDs & STIs
    August 27-29, 2018 Zurich, Switzerland
  • 6th International Conference on HIV/AIDS , STDs and STIs
    October 29-30, 2018 San Francisco, USA

Article Usage

  • Total views: 8298
  • [From(publication date):
    October-2016 - May 21, 2018]
  • Breakdown by view type
  • HTML page views : 8227
  • PDF downloads : 71
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7